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Abstract
Renal transplantation (RTx) is the treatment-of-choice for a significant number of patients 
with end-stage renal disease. Despite recent accomplishments, both surgical and medical 
complications still exist. Urinary tract infection (UTI) is the most common infectious com-
plication after RTx, while asymptomatic bacteriuria is the most common manifestation of 
bacteriuria. UTI can impair graft function, potentially reducing graft and patient survival. 
The aetiology changes with time after RTx. The epidemiology of most of these infections is 
also changing with resistant organisms being isolated more often than in the past. Several 
factors increase the risk of infection in RTx patients, and the presence of multiple risk 
factors in the same patient is not uncommon. These include immunosuppression, urinary 
flow impairment (most often caused by stenosis or strictures at the vesicoureteral junc-
tion, benign prostate hypertrophy or vesicoureteral reflux), and treatment-related factors 
such as the use of catheters and double-J stents. Early diagnosis and effective treatment 
are key elements in salvaging both the allograft and the patient. This chapter reviews 
the definitions, epidemiology, microbiology, screening, clinical manifestations, diagno-
sis, impact on renal allograft function, evaluation after diagnosis, treatment, prevention 
including long-term prophylaxis, and the unique challenges of diagnosing and managing 
recurrent bacterial UTIs in a RTx care setting.
Keywords: urinary tract infections, renal transplantation, treatment, prevention, renal 
allograft function
1. Introduction
Kidney transplantation is the renal replacement therapy of choice for the constantly 
increasing number of patients with end-stage renal disease (ESRD). The huge headway 
in immunosuppressive treatment has resulted in improved renal graft survival rates, at 
the same time making infectious complications an even more common problem in the 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
renal transplant (RTx) population, with the urinary tract being the most prevalent infection 
site. Apart from immunodeficiency resulting from the use of immunosuppressive drugs, 
RTx patients often suffer from numerous urological malformations, vesicoureteral reflux 
(VUR) that is a permanent symptom after RTx, and are exposed to invasive diagnostic and 
therapeutic procedures involving the urinary tract. That is why urinary tract infections 
(UTIs) are the most common infectious complication among RTx recipients with up to 60% 
prevalence during the first year post-transplant [1, 2]. UTIs are important not only because 
of the scale of the problem but due to their potential negative influence on graft and RTx 
recipients’ outcomes.
2. Epidemiology
Urinary tract infections (UTIs) are major causes of morbidity and hospitalization in renal 
transplant recipients. Infections, with the urinary tract as a major site, are the most common 
cause of acute kidney allograft injury, and prevalence of UTI-associated acute kidney injury 
far outnumbers episodes of acute rejection and calcineurin inhibitor toxicity [3].
There is a wide variation in the reported incidence of UTIs, most likely associated with 
differences in the definition of UTI, length of follow-up and variation in the use of post-
transplant antibiotic prophylaxis. In a recently published meta-analysis on the prevalence 
and predictive factors of UTI in patients undergoing renal transplantation that included 13 
studies with a total of 3364 patients evaluated, 1033 (30.71%) had UTIs [4]. The included 
studies provided different estimates of prevalence, which ranged from 16.0 to 75.0%, and 
the pooled prevalence of UTIs was 38% (95% CI, 29–47%; p < 0.01). Of note, RTx recipi-
ents followed for 1–2 years had significantly higher prevalence than those followed for 
2–5 years (34 vs. 43%).
3. Definitions
All UTIs can be classified into one of the four following categories:
(1) Asymptomatic bacteriuria (AB), defined as isolation of bacterial strain in quantitative 
counts ≥105 CFU in a clean-catch voided urine specimen in the absence of any symptoms 
of lower or upper UTI or <105 CFU in patients treated with antibiotics or ≥103 CFU in a 
single catheterized urine specimen, irrespective of the presence of leukocyturia.
(2) Lower UTI, which is the presence of bacteriuria and clinical manifestations of dysuria, 
frequency or urinary urgency and fever <38°C in the absence of acute graft pyelonephritis 
(AGPN) criteria.
(3) Upper UTI (AGPN), defined by the presence of significant bacteriuria, fever >38°C and/
or graft pain and/or acute graft function impairment.
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(4) Urosepsis—life-threatening organ dysfunction caused by a dysregulated host response 
to the upper UTI.
Recurrent infections are defined as 3 or more episodes of symptomatic UTIs over a 12-month 
period or 2 episodes in the previous 6 months and can be divided into:
(1) Relapses: defined as the isolation of the same microorganism that caused the preceding 
infection in a urine culture obtained ≥2 weeks after finishing the previous treatment. The 
isolation of the same microorganism that caused the preceding infection in a urine culture 
obtained <2 weeks after finishing the previous treatment should be considered a treatment 
failure.
(2) Reinfections: defined by a new episode of UTI with the isolation of an agent other than the 
one that caused the previous infection.
Definitions of multidrug-resistant (MDR) bacterial infections:
(1) Criteria for multidrug-resistant (MDR) bacteria: non-susceptible to ≥1 agent in ≥3 antimi-
crobial categories or methicillin resistance in the case of S. aureus.
(2) Criteria for extensively drug-resistant (XDR) bacteria: non-susceptible to ≥1 agent 
in all but ≤2 categories (i.e. bacterial isolates remain susceptible to only one or two 
categories).
(3) Criteria for pan drug-resistant (PDR) bacteria: non-susceptible to all the antimicrobials.
(4) Heteroresistance is defined as the presence of mixed populations of drug-resistant and 
drug-sensitive cells in a single clinical specimen.
4. Predisposing factors for UTIs after RTx
Many factors are believed to contribute to the high incidence of UTI in RTx recipients. Some 
exist prior to transplant, including female gender, diabetes mellitus and underlying urinary 
tract abnormalities. Peri-transplant factors are often related to instrumentation of the urinary 
tract, including ureteral stenting and prolonged urinary catheterization. Additional risk fac-
tors contributing to UTI post-transplant include immunosuppression and graft dysfunction 
or rejection. It is noteworthy that so far no direct association has been found between the 
risk of UTI and dose or type of maintenance immunosuppression. It is the net state of immu-
nosuppression that impairs host defense capability against infections in general. Various 
authors have suggested different potential UTI risk factors, and their findings are not always 
consistent. The potential pre-, peri- and post-transplant risk factors for UTI in RTx recipients 
are shown in Table 1.
Of note, significant urine flow impairment, both existing pre-transplant or appearing post-
transplant, seems to be of major importance. The bladder outlet obstruction, particularly in 
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males, may not be appreciated until after the transplant, leading to prolonged instrumenta-
tion and an increased risk of UTI. The likelihood of AGPN development is 20-fold higher 
in patients with vesicoureteral reflux (VUR) or strictures at the uretero-vesical junction or 
benign prostate hyperplasia (BPH). Active reflux has long been reported as being signifi-
cantly associated with poor graft outcome [5]. In a study by Dupont et al., VUR was found in 
almost half of RTx patients with recurrent UTIs, and patients with VUR were more prone to 
develop renal scarring than those without VUR [6]. On the other hand, in a recent study by 
Margreiter et al., 40% of 646 consecutive RTx recipients were diagnosed with VUR by voiding 
cystourethrography, and VUR did not affect the occurrence of UTIs. Simple UTI was diag-
nosed in 24.7% of patients with VUR and 27.2% of patients without VUR (p = 0.78). Recurrent 
UTIs were noted in 4.2% (with VUR) versus 3.9% (without VUR) of the enrolled patients 
(p = 0.67). However, the authors did not analyze the incidence of UTI according to VUR 
grade [7]. In a retrospective cohort of 23,622 adult male primary RTx recipients, also benign 
prostate hyperplasia was independently associated with recurrent UTI [8]. Considering the 
significant influence of urinary flow abnormalities on the likelihood of AGPN development, 
we would strongly recommend examination for VUR or urine flow obstruction even at the 
first AGPN episode.
5. Impact on renal allograft function
The reports on the influence of UTIs on long-term kidney allograft function are inconsistent. 
The true impact of the whole spectrum of clinical manifestations of UTIs, on patient and graft 
outcome, so far has not been established. The general assumption is that asymptomatic bacte-
riuria (AB) is benign, as opposed to acute graft pyelonephritis or urosepsis. Still, the paucity of 
symptoms might be attributable to immunosuppression with actual ongoing inflammation of 
unrecognized significance. In one small study, kidney transplant patients with asymptomatic 
bacteriuria had elevated urine IL-8 level; and the authors hypothesized that this phenomenon 
may reflect an impaired immune response to bacterial infection and occult inflammatory pro-
cess in the urinary tract [9]. Pellé et al. showed that acute graft pyelonephritis (AGPN) was 
Pre-transplant Peri-transplant Post-transplant
Urine flow impairment
Female gender
Diabetes
Urinary tract anomalies
Glomerulonephritis
Ureteral stents
Bladder instrumentation
Deceased-donor grafts
Double kidney transplants
Urine flow impairment
• Vesicoureteral reflux (VUR)
• Strictures at the uretero-vesical junction
• Benign prostate hyperplasia
Immunosuppression
Acute rejection
Reduced graft function
Table 1. Risk factors for UTI in renal transplant recipients.
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an independent risk factor for the decline in renal function in a group of 172 RTx recipients 
[10]. Also a more recent study analyzing the effects of recurrent UTIs on graft and patient 
outcomes, in a population of 2469 RTx recipients, showed both poorer graft and patient sur-
vival in patients with a history of ≥3 UTIs in any 12-month period or ≥2 UTIs in any 6-month 
period, irrespective of the causative organism [11]. However other reports did not confirm 
this relationship. Not only asymptomatic bacteriuria but also AGPN did not affect long-term 
renal graft function prognosis [12–15]. However, even if UTIs do not influence graft survival 
directly, they can pose a significant risk indirectly by leading to bacteraemia, acute rejection 
or cytomegalovirus (CMV) infection.
6. Aetiology and timing of infections
UTI after kidney transplantation is most often caused by Gram-negative organisms (around 
50–90%), with Escherichia coli as the most frequently isolated microorganism in urine cul-
tures, similarly to general population. However, aetiology differs between the early and late 
periods after RTx [16]. Enterococcus species has emerged as an important pathogen and now 
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Figure 1. Proportion of different causative agents according to the type of UTI (a) during the first month post-transplant 
and (b) during 2–12 months post-transplant [16].
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accounts for up to 30% of UTIs, especially in the first post-transplant month. In a study by 
Alangaden et al. Enterococcus spp. accounted for 33% of UTIs, but authors failed to identify 
any specific risk factor associated with the predominance of this uropathogen [17]. Also in a 
study by Bonkat et al., Enterococcus spp. were bacteria most commonly responsible for micro-
bial ureteral stent colonization in RTx recipients. The authors found two possible explana-
tions for this phenomenon. Enterococcus spp. possess biofilm formation properties on various 
kinds of indwelling medical devices; and routine urine cultures often fail to identify bio-
film forming Gram-positive pathogens, unlike the sonication technique used in that study 
to dislodge adherent microorganisms [18]. Another possible explanation of a high number 
of Enterococcus spp. infections is the routine use of cephalosporins in perioperative prophy-
laxis. This antibiotic acts against Gram-negative Bacilli, therefore it promotes selection of 
Enterococcus spp.
Beginning from the second month, Escherichia coli is the most frequently isolated causative agent, 
followed by Proteus spp., Klebsiella spp., Enterobacter spp. and Pseudomonas spp. (Figure 1).
7. Multidrug-resistant bacteria
With the widespread use of antibiotics, including the routine use of antimicrobial prophylaxis 
in RTx recipients, the prevalence of multidrug resistance (MDR) among uropathogenic bac-
teria is increasing, irrespectively of region and country. The most widely accepted definition 
of MDR includes lack of susceptibility to one or more agents in three or more antimicrobial 
categories active against the isolated bacteria. Of note, also extensively drug-resistant (XDR) 
and pan drug-resistant (PDR) strains have been identified.
In patients receiving trimethoprim-sulfamethoxazole prophylaxis, over 60% of UTIs have been 
reported as caused by trimethoprim-sulfamethoxazole-resistant organisms [19]. The treat-
ment of AB has also been associated with antimicrobial resistance. In a study of patients with 
asymptomatic E. coli or E. faecalis bacteriuria, treatment led to selection of resistant organisms 
in almost 80% of treated cases [20]. The emergence of ESBL-producing, or carbapenemase-
producing, organism pathogens has been the most important threat in nosocomial infections 
in recent years [21]. Although antibiotic resistance has been a concern since the introduc-
tion of penicillin, the past two decades have seen a marked increase in resistance, especially 
related to beta-lactams. Resistance in Gram-negative pathogens continues to increase, with 
multidrug resistance in the Enterobacteriaceae becoming one of the most important crises faced 
by the medical community. A major contributing factor is the acquisition of large plasmids 
that can encode resistance factors for multiple drug classes. As seen from the recent literature, 
organisms such as E. coli and the Klebsiella are acquiring more diverse integrons and trans-
posons that are included in a multiplicity of transferable plasmids capable of encoding every 
class of beta-lactamase.
It seems that immunosuppression may influence the resistance of enterococcal spp. to 𝛽-lactam-
based antibiotics by affecting the expression of the penicillin-binding proteins (PBPs). In entero-
coccal strains isolated from RTx patients, the expression of the PBP5 gene was higher than in 
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commensal strains. As cyclosporine seemed to promote higher expression of PBP5 than tacro-
limus, 𝛽-lactam antibiotics may be more effective when tacrolimus-based immunosuppression 
protocols are implemented [22].
In a recently published study analyzing recurrent UTIs in a cohort of 2469 RTx recipients, 
the authors found pronounced differences in antimicrobial resistance patterns between non-
recurrent and recurrent UTIs [11]. Isolates from the cases of recurrent UTIs were more likely 
to be resistant to first- and third-generation cephalosporins, trimethoprim-sulfamethoxazole, 
nitrofurantoin and fluoroquinolones, to extended-spectrum b-lactams and aminoglycosides.
In a retrospective case series by Winters et al., 85% of solid-organ transplant recipients diag-
nosed with infection due to ESBL-producing bacteria received inadequate empiric therapy 
[23]. This means that all RTx recipients with a history of UTI due to ESBL-producing Gram-
negative pathogens, presenting with symptoms of a new UTI, should receive an empiric 
therapy with a carbapenem until a urine culture result with susceptibility profile is available.
8. Diagnosis
UTIs in RTx recipients may either be asymptomatic or have an atypical clinical presentation. 
Therefore the diagnosis based solely on clinical grounds may be of questionable accuracy. 
What is more, every symptomatic, either lower or upper UTI in any transplant recipient, is 
considered complicated: as it is associated with structural and functional abnormalities of 
the genitourinary tract and immunocompromised status that increases the risk for acquiring 
an infection or of failing therapy. For this reason urine cultures should be obtained in every 
single case, in order to base therapy upon susceptibility pattern determinations.
9. Asymptomatic bacteriuria
Asymptomatic bacteriuria is a frequent finding in kidney allograft recipients, with almost 40% 
incidence [16]. So far there are no evidence-based recommendations for screening and treatment 
of AB in renal transplant recipients, because sufficient data is lacking [24]. The American Society 
of Transplantation Infectious Diseases Guidelines recommend limiting screening to the first 
post-transplant month, but these recommendations are mostly expert opinion [25]. Fiorante et al. 
showed that the incidence of AGPN was significantly higher in patients with a history of multiple 
episodes of AB than in patients without, despite or due to the provided antibiotic treatment [26].
Patients with no episodes of AB seem to develop significantly fewer symptomatic infections 
than patients with a history of recurrent AB. As reinfections seem to outnumber relapses and 
only a very few episodes of symptomatic UTIs are preceded by AB with the same causative 
agent in patients with a history of recurrent AB, it seems that AB is more of a marker of 
increased susceptibility to infections, not a direct risk factor [16]. This is in agreement with the 
findings from a non-transplant population of young women, where the treatment of AB in 
patients affected by recurrent UTI was associated with a higher rate of symptomatic UTI [27]. 
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The authors hypothesized that this phenomenon resulted from ecological effects of antibacte-
rial agents on the human microflora. However, Rice et al. found an association between AB 
progression to systemic infection with acute kidney allograft injury and a unique pattern of 
adherence factors that is P fimbriae but not Dr. fimbriae expression [28]. So, AB might be an 
actual risk factor for symptomatic UTIs depending on the virulence of uropathogens.
A number of studies attempted to elucidate if the treatment of AB in RTx patients is in fact 
helpful or harmful in preventing symptomatic infections [19, 20]. One retrospective obser-
vational study included a total of 112 patients with AB. The decision as to whether, or not, 
to treat AB was made by the attending physician. The primary outcome, defined as hospital-
ization for symptomatic UTI or a 25% decline in the eGFR, occurred more frequently among 
patients treated with antibiotics. However, the authors called attention to the fact that those 
treated patients may have initially been at higher risk for adverse outcomes, thus mask-
ing the benefit of the treatment [19]. Another retrospective study included 77 RTx recipi-
ents who developed 334 AB episodes later than 1-month post transplantation. AB episodes 
were classified into four groups depending on the presence of pyuria and grade of bacte-
riuria. Spontaneous bacterial clearance occurred in 59% of untreated episodes. The resolu-
tion of bacteriuria was not more frequent in treated, as compared to untreated, episodes. 
However, antibiotic treatment in patients with high-grade bacteriuria and concurrent pyuria 
resulted more frequently in negative control cultures than untreated episodes. The authors 
concluded that a watch-and-wait strategy for bacteriuria in the absence of pyuria might be 
safe in the RTx population [20]. In 2016, the results of a randomized controlled study were 
published. Systematic screening and treatment of AB beyond the second month after trans-
plantation provided no apparent benefit among KT recipients when the occurrence of acute 
pyelonephritis at 24-month follow-up was considered. The treatment also did not affect the 
secondary outcomes, which included lower UTI, acute rejection, Clostridium difficile infec-
tion, colonization or infection by multidrug-resistant bacteria, graft function and all-cause 
mortality [29].
10. Treatment
Selection of initial empiric treatment should be based on local epidemiological data and the 
patient’s history of resistant organisms. Once susceptibility data are available, the initial ther-
apy should be deescalated, so that the most narrow-spectrum antibiotic is used to complete 
the course of therapy. Care should be taken to avoid treating asymptomatic patients, in order 
to reduce the possibility of infection with MDR pathogens.
Lower UTIs require minimum 7-day therapy with an effective agent while upper UTIs at least 
2–3 weeks. The resolution of infection should be demonstrated before the cessation of treat-
ment. Stents or catheters may be covered with bacterial biofilm, so their removal is generally 
required for resolution of UTI. For empirical treatment of suspected bacterial infections in RTx 
patients, the selection of antimicrobial agents should be based on local epidemiological data 
and on the patient’s history of colonization or infection with antibiotic-resistant organisms.
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There is no evidence to support the use of combination antibiotic therapy for the treatment of 
ESBL, but in haemodynamically unstable or critically ill patients, adding an aminoglycoside to 
carbapenem seems a reasonable strategy. Amoxicillin-clavulanate and fosfomycin showed a clin-
ical efficacy of 84 and 93%, respectively, in the treatment of cystitis caused by ESBL-producing 
E. coli but only when the isolate showed susceptibility to those drugs [30]. Other options in the 
case of proven susceptibility include tigecycline, cotrimoxazole, quinolones and nitrofurantoin.
The combination antibiotic therapy is a standard of care in carbapenemase-producing Entero­
bacteriaceae infections [31, 32]. Colistin is the most active agent against these strains and 
should be considered the basis of treatment in most patients [33]. The options for the use 
of combination antibiotic therapy include aminoglycosides, fosfomycin or even high-dose 
carbapenems [31, 32, 34]. Tigecycline could represent an optimal choice for patients with 
co-infection with additional MDR pathogens [e.g. vancomycin-resistant Enterococci (VRE) or 
methicillin-resistant Staphylococcus aureus (MRSA)].
In the case of severe infection with sepsis, the option of reduction/discontinuation of immuno-
suppression together with surgical/urological intervention should also be considered.
In severe upper UTIs and/or recurrent infections, imaging should always be obtained to rule 
out structural causes or persistent foci of infection. Ultrasound may confirm the presence of 
hydronephrosis. When there are no visible structural abnormalities on ultrasound, it may 
be necessary to perform fluoroscopic voiding cystourethrogram to diagnose severe vesico-
ureteral reflux (VUR), computed tomography urography to visualize the cause of urine flow 
obstruction or uroflowmetry to recognize the problem with delayed bladder emptying. In 
elderly RTx recipients, the aforementioned functional abnormalities may be secondary to 
benign prostate hyperplasia (BPH). Since most patients undergoing dialysis are oliguric or 
anuric, urinary obstruction due to BPH and related lower urinary tract symptoms become 
evident after RTx and restoration of diuresis. As opposed to native kidneys, the transplanted 
kidney’s ureter is shorter, and there is no valve at the vesicoureteral junction preventing back-
flow, so low-grade BPH may cause symptoms that would not be present in a non-RTx patient. 
Medical therapy of BPH, both pharmacologic and surgical, such as transurethral resection of 
the prostate is safe and improves urinary flow and bladder emptying, to allow a significant 
and durable improvement of the kidney allograft function.
11. Prevention and prophylaxis
Appropriate attention should be given to the prevention of UTI with correction of structural 
abnormalities of the urinary tract in the potential RTx recipients prior to transplantation. Any 
type of voiding dysfunction should be considered and addressed.
In the immediate post-transplant period, vigilance for donor-transmitted infection is important, 
together with routine perioperative antibiotic prophylaxis recommended by the hospital’s epi-
demiologist, taking into account current antibiotic resistance of Gram-negative strains. In the 
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case of a positive donor’s or organ preservation fluid cultures, the antibiotic should be chosen 
according to susceptibility profiles. The use of indwelling urethral catheters and ureteral stents 
should be minimized.
Patients should be instructed to drink a lot of fluids and urinate frequently, without waiting 
for the urge to urinate.
There is no consensus regarding the optimal strategy and duration of recurrent UTI prophy-
laxis, so the decision to give it, or not, depends on the experience of the treating physician. 
Traditionally trimethoprim/sulfamethoxazole prophylaxis has been used as the prevention of 
both asymptomatic bacteriuria/UTI and Pneumocystis pneumonia after RTx. However, over 
the past few years, it has become less effective as uropathogens have become more resistant to 
this regimen. Of note, ESBL-producing E. coli are usually susceptible to nitrofurantoin, while 
most Klebsiella spp. strains are resistant to this antibiotic.
Several possibilities exist in an attempt to mitigate the damage caused by resistant pathogens. 
In the general population, there are ongoing attempts to use nonantibiotic strategies, such as 
cranberry products, D-mannose, probiotics, immunoactive prophylaxis with several types of 
vaccines, intravesical glycosaminoglycan replenishment therapy with the use of chondroitin 
sulfate and low molecular weight hyaluronic acid in the treatment and/or prevention of recur-
rent UTIs [35]. So far the use of all these products has not been extensively studied in RTx 
population, except for single-case reports on the use of cranberry products. Little information 
is also available about the usefulness of intestinal decolonization in RTx patients.
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